Published on 24 March 2023
Description:
It’s live, direct and covering all the most pressing pharma issues! Yes, the April edition has landed. We’re talking about diversity in clinical trial s and why this most fundamental principle can accelerate drug delivery. On the subject of principles, we’re taking a magical mystery tour of our industry through the prism of the most agenda topping conversation of our times – sustainability!
Categories:
PharmaTimes29 articles from this collection:
Cover
2 - FlyPharma Europe
3 - From the editor
This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK, and again there is much cause for celebration. As the analysis shows, a relentless focus on innovation and a determination to solve problems hindering patient outcomes are key traits that have helped those at the top shine in a sector that saw average growth of 33% in 2020.
4-5 - Contents
6 - NEWS: Treatments
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the potential reclassification of two progestogen-only, oral contraceptive pills containing desogestrel: Lovima 75mcg and Hana 75mcg film-coated tablets.
7 - NEWS: NHS
8 - NEWS: Collaboration
9 - NEWS: Conditions
10-11 - COVER STORY: A design for life
12 - GENOMIC TESTING: Uncomfortable truths
13 - SUSTAINABILITY: In an ideal world
14-15 - FLYPHARMA EUROPE - Vienna – 2023 conference officially launches
16 - AI: The holy grail for pharma?
17-19 - INDUSTRY: Moving on up
20-21 - DIGITAL: Digital love
22 - THOUGHT LEADER: Paper View
23 - SAMEDAN
24-25 - INCLUSIVITY: Talking the talk
26 - SUSTAINABILITY: Time waits for no one
27 - THOUGHT LEADERSHIP
28-29 - DIGITAL HEALTH: Evolution energised
30-31 - MEDICINE: Optimise this!
32 - ADVERTISEMENTS
33 - SUSTAINABILITY: Countdown conundrum
34-35 - NHS: Digital dichotomy
36-37 - Your moves
38 - THOUGHT LEADER: Connect More
39 - Samedan
40 - FlyPharma Europe
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.